title: Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge.
abstract: Approximately 20% of stage 4 high-risk neuroblastoma patients are alive and disease-free 5 years after disease onset while the remaining experience rapid and fatal progression. Numerous findings underline the prognostic role of methylation of defined target genes in neuroblastoma without taking into account the clinical and biological heterogeneity of this disease. In this report we have investigated the methylation of the PCDHB cluster, the most informative member of the "Methylator Phenotype" in neuroblastoma, hypothesizing that if this epigenetic mark can predict overall and progression free survival in high-risk stage 4 neuroblastoma, it could be utilized to improve the risk stratification of the patients, alone or in conjunction with the previously identified methylation of the SFN gene (14.3.3sigma) that can accurately predict outcome in these patients. We have utilized univariate and multivariate models to compare the prognostic power of PCDHB methylation in terms of overall and progression free survival, quantitatively determined by pyrosequencing, with that of other markers utilized for the patients' stratification utilizing methylation thresholds calculated on neuroblastoma at stage 1-4 and only on stage 4, high-risk patients. Our results indicate that PCDHB accurately distinguishes between high- and intermediate/low risk stage 4 neuroblastoma in agreement with the established risk stratification criteria. However PCDHB cannot predict outcome in the subgroup of stage 4 patients at high-risk whereas methylation levels of SFN are suggestive of a "methylation gradient" associated with tumor aggressiveness as suggested by the finding of a higher threshold that defines a subset of patients with an extremely severe disease (OS <24 months). Because of the heterogeneity of neuroblastoma we believe that clinically relevant methylation markers should be selected and tested on homogeneous groups of patients rather than on patients at all stages.
authors.affiliation: Tumor Genetics and Epigenetics, IRCCS AOU San Martino-IST, Genova, Italy. barbara.banelli@istge.it
authors.forename: Barbara
authors.initials: B
authors.lastname: Banelli
authors.forename: Domenico Franco
authors.initials: DF
authors.lastname: Merlo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Allemanni
authors.forename: Alessandra
authors.initials: A
authors.lastname: Forlani
authors.forename: Massimo
authors.initials: M
authors.lastname: Romani
mesh_terms: D048948:14-3-3 Proteins / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics; D002675:Child, Preschool; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation / Q000235:genetics*; D018572:Disease-Free Survival; D005095:Exoribonucleases / Q000235:genetics; D006801:Humans; D007223:Infant; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology*; D010641:Phenotype; D011379:Prognosis; D012306:Risk
chemical_list: D048948:14-3-3 Proteins; D014408:Biomarkers, Tumor; D005095:Exoribonucleases; C413442:SFN protein, human